A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease

Charles KN Chan MD¹, François Maltais MD², Chris Sigouin MSc³, Jennifer M Haddon MSc⁴, Gordon T Ford MD⁵; on behalf of the SAFE Study Group

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) who smoke have a greater annual rate of decline in forced expiratory volume in 1 s (FEV₁) than those patients who have stopped smoking.

OBJECTIVES: To assess the effect of tiotropium on pre-dose (tough) FEV₁ in patients with COPD followed in Canada.

METHODS: A total of 913 patients were randomly assigned to receive either tiotropium 18 μg once daily (n=608) or placebo (usual care minus inhaled anticholinergics) (n=305) for 48 weeks in the present randomized, double-blind, parallel-group study. The effect of tiotropium on measurements of lung function (FEV₁, FEV₆ and forced vital capacity), symptoms, health-related quality of life (St George’s Respiratory Questionnaire) and exacerbations were examined.

RESULTS: Tiotropium improved trough FEV₁ in both current and ex-smokers compared with placebo. Baseline FEV₁ in smokers and ex-smokers was 1.03 L and 0.93 L, respectively (P<0.001). At week 48, the mean difference between the tiotropium and placebo group was 0.14±0.04 L (P<0.001) in the smoker group and 0.08±0.02 L (P<0.0001) in the ex-smoker group. Tiotropium also significantly improved trough forced vital capacity and FEV₁ compared with placebo throughout the treatment period (P<0.05, for all). Furthermore, tiotropium significantly improved the St George’s Respiratory Questionnaire total score compared with placebo at week 48 (40.9 versus 43.7 units, P<0.005).

CONCLUSIONS: Compared with the placebo group, tiotropium provides sustained improvements in lung function in patients with COPD, with improvements for smokers and ex-smokers.

Key Words: COPD; Placebo; Randomized; Smoking; Tiotropium

Chronic obstructive pulmonary disease (COPD) is a major public health burden (1). It is currently ranked as the fourth leading cause of morbidity and mortality in Canada (2), and further increases in prevalence are predicted (3). Cigarette smoking is the major known risk factor for COPD. Cigarette smokers have a higher prevalence of respiratory symptoms and lung function abnormalities, a greater annual rate of decline in forced expiratory volume in 1 s (FEV₁) and a greater COPD mortality rate than nonsmokers (1,4,5). Smoking cessation is the only intervention that has been shown to reduce the rate of decline in FEV₁ in patients with COPD (6). Smoking affects the response to corticosteroids in asthma, and smoking cessation may at least partially restore corticosteroid responsiveness in asthmatic ex-smokers (7). However, because tiotropium acts on the acetylcholine receptors rather than the steroid receptors, there may be a different effect and, hypothetically, smoking status may affect the response to tiotropium. From the results of the Lung Health Study (8), it appears that smoking...
cessation is associated with an increase in bronchodilator response, so there may be a differential response to anticholinergic treatment in smokers and ex-smokers. Previous studies with tiotropium have documented smoking status before randomization but patients were not prospectively stratified to assess the potential interaction with treatment (9-14), hence the rationale to assess smoking status in this population.

Bronchodilators effectively control the symptoms of COPD and are currently the mainstay of treatment. Anticholinergic bronchodilators are one of the drug classes recommended by several international guidelines for first-line maintenance treatment of COPD (1,15,16). Tiotropium is a once-daily anticholinergic bronchodilator that acts through prolonged M1-receptor blockade. One-year studies have demonstrated that tiotropium significantly improves lung function, reduces dyspnea and the incidence of exacerbations, and enhances health-related quality of life (HRQL) compared with either placebo or ipratropium (9,10). Two six-month trials compared the bronchodilator efficacy of once-daily tiotropium with the twice-daily long-acting beta2-agonist (LABA) salmeterol, and confirmed that tiotropium is effective in improving lung function and other clinical end points (12). As part of the continuing evaluation of tiotropium in Canada, it is important to assess the efficacy and safety of tiotropium in a Canadian health care setting. In addition, the current study was more reflective of standard care and use of tiotropium in Canada, it is important to assess the efficacy and safety of tiotropium in a Canadian health care setting. In addition, the current study was more reflective of standard Canadian pharmacotherapy for patients with moderate COPD (15) because the placebo group was allowed to remain on most of their respiratory medications except for the class of drug under study (anticholinergics).

The primary objective of the present trial was to assess the effect of tiotropium on FEV1 in patients with COPD. The effects of tiotropium in smokers and ex-smokers as well as its effect on various other patient-reported outcomes, including symptoms, HRQL and exacerbations, were also examined in the Canadian health care setting.

PATIENTS AND METHODS

Study design

The present study was a one-year, multicentre, randomized, double-blind, placebo-controlled, parallel-group study comparing the effect of tiotropium on morning pre-dose (ie, trough) FEV1 in patients with COPD. The trial (study protocol 205.259) was performed at 101 centres in Canada involving 72 specialists and 29 general practitioners. The study protocol was approved by the Therapeutic Products Directorate of Health Canada and an Institutional Review Board (local or central as required), and all participants gave written informed consent.

Screening assessments were made at visit 1 and, following a two-week run-in period, eligible patients were randomly assigned to receive either tiotropium 18 μg once daily or placebo for 48 weeks (in a ratio of 2:1), delivered via the HandiHaler (Boehringer Ingelheim, Germany). The assessments made at visit 2 constituted the baseline values. The study was concluded with a two-week follow-up period. During the treatment period, patients were permitted oral corticosteroids (at a stable dose of 10 mg or less of prednisone daily or equivalent), stable doses of inhaled corticosteroids, theophylline preparations, mucolytic preparations (not containing bronchodilators), LABAs and, for acute symptom relief, as-needed salbutamol metered-dose inhaler. Patients were not allowed to use inhaled anticholinergics (other than the study drug) or oral beta2-agonists during the treatment period. To treat COPD exacerbations during the trial, the investigators were permitted to administer any additional medication deemed necessary.

Patients

Male and female outpatients aged 40 years or older, with a clinical diagnosis of COPD (FEV1 65% predicted or less and FEV1/forced vital capacity [FVC] 70% or less) (17) were considered for inclusion in the present study. Participants were required to have a smoking history of 10 pack-years or greater. The inclusion criteria relating to ‘exacerbation history’ initially required that patients had experienced one or more exacerbations within the past year (requiring treatment with antibiotics and/or oral steroids), but not within the six weeks before entering the study. However, due to slower than expected enrolment, this criterion was amended to include patients with fewer exacerbations (one exacerbation in the past two years).

Exclusion criteria were history of asthma, allergic rhinitis or atopy; a recent lower respiratory tract infection or any exacerbation (within the previous six weeks); a recent history of myocardial infarction (within the previous six months) or cardiac arrhythmia requiring drug therapy; and oral corticosteroid use at unstable doses during the six weeks before entering the study or at a stable dose exceeding the equivalent of 10 mg prednisone daily. In addition, those patients with a significant disease other than COPD that would put the patient at risk because of participation in the study, or patients with a disease that may have influenced the results of the study, were not enrolled.

Clinical assessments

Spirometry was conducted in accordance with American Thoracic Society standards with office-based spirometry (18). The types of devices were not consistent but they were required to be American Thoracic Society approved. All spirometric tests were conducted in triplicate and the highest acceptable measurements were used in subsequent analyses. To ensure standardized conditions on spirometry test days, patients discontinued short-acting beta2-agonists 6 h before dosing (trough). Trough response was defined as the pre-dose value at each clinic visit after randomization, ie, 23 h to 24 h after the previous dose of trial medication.

HRQL was determined using the St George’s Respiratory Questionnaire (SGRQ) before dosing on day 1 as well as after 30 and 48 weeks of treatment. The SGRQ is a validated 76-item questionnaire, split into three subscores – symptoms: assessing distress due to respiratory symptoms; activity: assessing the effects of breathlessness on mobility and physical activity; and impacts: assessing the psychosocial impact of disease. The SGRQ total score is a composite of all three subscores. Scores are weighted and range from 0 to 100, with higher scores
indicating a poorer HRQL. A difference of 4.0 or more units is considered clinically meaningful (19).

Detailed information on exacerbations and associated hospitalizations, and the number of courses of both oral steroids and antibiotics administered for the treatment of exacerbations were collected at each clinic visit. Data of health care use specifically related to COPD were collected on a separate page of the case report form. An exacerbation was defined as a complex of respiratory symptoms (new onset or an increase in at least one of cough, sputum, sputum purulence, dyspnea, wheeze, chest discomfort) lasting at least three days and requiring treatment with antibiotics and/or systemic steroids.

Adverse events were monitored throughout the treatment period.

Statistical analysis

Descriptive statistics (mean ± SD, and/or frequency, per cent) for patient characteristics at screening and adverse events are presented by treatment groups, tiotropium and placebo.

Change in FEV₁, FVC, FEV₆, SGRQ total score and sub-scores, and rescue medication use were compared between treatment groups, using an ANCOVA with the term treatment and baseline as a covariate. These analyses were applied to the full analysis set (FAS) patient population with the last observation carried forward method, except when patients discontinued because of worsening COPD, when the least favourable data before discontinuation were carried forward. The FAS population included all patients who were randomly assigned, took at least one dose of study medication, and had a valid baseline measurement and an additional measurement after at least one week of multiple dosing.

The number (per cent) of patients with at least one COPD exacerbation, and the number (per cent) of patients with at least one hospitalization due to a COPD exacerbation were each compared across treatment groups using the Fisher’s exact test (two-sided). The number of COPD exacerbations, COPD exacerbation days, hospitalizations due to a COPD exacerbation, hospitalization days due to a COPD exacerbation and courses of steroids/antibiotics taken during a COPD exacerbation episode were each compared across treatment groups using Poisson regression with extent of exposure (minus the duration of events) as the offset. These analyses included patients who were randomly assigned and who took at least one dose of study medication.

As specified by the protocol, the planned analysis allowed for the stepwise further analysis of the difference in trough FEV₁ at 48 weeks in the smoker and ex-smoker groups if a positive result was demonstrated in the treatment group comparison.

Univariate analyses, including one-way ANOVAs and Fisher’s exact tests (two-sided), were applied to continuous and categorical variables, respectively, to compare smoker and ex-smoker patient characteristics at screening. These analyses included patients who were randomly assigned and who took at least one dose of study medication.

Within the smoker and ex-smoker groups, the change in FEV₁ and the SGRQ total score were compared between treatment groups (tiotropium and placebo) using an ANCOVA with the term treatment and baseline as a covariate. The FAS was used in these analyses.

The SAS System for Windows version 8.2 (SAS Institute Inc, USA) was used to perform the analyses and a P<0.05 was considered statistically significant.

Sample size

A sample size of 900 patients (tiotropium: 600 patients; placebo: 300 patients) was estimated to provide 90% power to detect a between-group difference of 0.13 L in the primary end point (FEV₁ trough response) based on a standard deviation of 0.215 L at a 5% level of alpha confidence interval. The initial sample size calculation included three comparator groups: frequent smokers, infrequent smokers and ex-smokers. However, due to lower than expected recruitment, an amendment was created to reduce the number of comparator groups from three to two (smokers and ex-smokers).

RESULTS

A total of 913 patients were randomly assigned to one of two groups and treated, with 608 receiving tiotropium and 305 receiving placebo (Table 1). The two treatment groups were well matched at screening for demographics, disease characteristics and concomitant medication use (Table 2).

The patient characteristics at screening were compared between the smoker and ex-smoker groups. The ex-smokers were significantly older, and had a higher body mass index, lower values for lung function parameters and a lower SGRQ total score (Table 3).

More patients in the tiotropium group completed the trial than did those in the placebo group (77.8% versus 72.5%), which created a potential bias. Additionally, at day 50 of treatment, the discontinuation rate was higher in the placebo group (12.5%) than in the tiotropium group (7.4%). This resulted in an exposure difference to treatment, with the mean difference between tiotropium and placebo groups being 19 days. The characteristics of the drop outs at baseline suggest that these patients had more severe COPD; they had lower lung function, greater use of respiratory medications and almost double the use of oxygen therapy compared with the study completers (Table 4).

Spirometry

Patients in the tiotropium group showed a statistically significant increase in trough FEV₁, compared with the placebo group at week 48 (1.07 L versus 0.97 L; mean (± SE) difference: 0.10±0.02 L; P<0.0001). A statistically significant mean difference of 0.10 L was first seen after two weeks of multiple dosing and was maintained throughout the trial (P<0.0001) (Figure 1A).

In addition, within both the smoker and ex-smoker groups, the tiotropium group showed a statistically significant increase
TABLE 2
Patient characteristics at screening by treatment group

<table>
<thead>
<tr>
<th></th>
<th>Tiotropium</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total randomized, n</td>
<td>608</td>
<td>305</td>
</tr>
<tr>
<td>Male, %</td>
<td>59</td>
<td>61</td>
</tr>
<tr>
<td>Age, years</td>
<td>66.8±8.7</td>
<td>66.9±8.1</td>
</tr>
<tr>
<td>Duration of COPD, years</td>
<td>9.9±8.1</td>
<td>9.9±7.9</td>
</tr>
<tr>
<td>Smoking history, pack-years</td>
<td>50.2±22.6</td>
<td>51.0±26.3</td>
</tr>
<tr>
<td>Current smoker, %</td>
<td>32</td>
<td>30</td>
</tr>
<tr>
<td>FEV1, L</td>
<td>0.97±0.39</td>
<td>0.96±0.38</td>
</tr>
<tr>
<td>FEV1, % predicted</td>
<td>39.4±13.4</td>
<td>39.3±13.6</td>
</tr>
<tr>
<td>FVC, L</td>
<td>2.11±0.76</td>
<td>2.11±0.73</td>
</tr>
<tr>
<td>FEV1/FVC, %</td>
<td>1.92±0.62</td>
<td>1.97±0.59</td>
</tr>
<tr>
<td>Respiratory medication use, n (%)</td>
<td>46.4±11.6</td>
<td>46.3±11.8</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD unless otherwise indicated. *Forced expiratory volume in 6 s (FEV6) was only measured at qualified sites, and includes 95 completers and 24 drop outs. COPD Chronic obstructive pulmonary disease; FEV1 Forced expiratory volume in 1 s; FVC Forced vital capacity.

TABLE 3
Patient characteristics at screening: Smoker versus ex-smoker

<table>
<thead>
<tr>
<th></th>
<th>Smoker</th>
<th>Ex-smoker</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total randomized, n</td>
<td>287</td>
<td>626</td>
<td></td>
</tr>
<tr>
<td>Male, %</td>
<td>52.3</td>
<td>63.3</td>
<td>0.0018</td>
</tr>
<tr>
<td>Age, years</td>
<td>63.3±8.8</td>
<td>68.4±8.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>26.07±6.17</td>
<td>27.14±5.81</td>
<td>0.0113</td>
</tr>
<tr>
<td>Duration of COPD, years</td>
<td>9.5±8.0</td>
<td>10.1±8.1</td>
<td>NSD</td>
</tr>
<tr>
<td>Smoking history, pack-years</td>
<td>47.9±22.1</td>
<td>51.6±24.6</td>
<td>0.0300</td>
</tr>
<tr>
<td>FEV1, L</td>
<td>1.03±0.41</td>
<td>0.93±0.37</td>
<td>0.0003</td>
</tr>
<tr>
<td>FEV1, % predicted</td>
<td>41.4±13.4</td>
<td>38.4±13.4</td>
<td>0.0016</td>
</tr>
<tr>
<td>FVC, L</td>
<td>2.12±0.77</td>
<td>2.11±0.74</td>
<td>NSD</td>
</tr>
<tr>
<td>FEV1/FVC, %</td>
<td>2.13±0.72</td>
<td>1.88±0.54</td>
<td>0.0270</td>
</tr>
<tr>
<td>SGRQ total score1</td>
<td>49.4±10.9</td>
<td>44.9±11.7</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD unless otherwise indicated. *Forced expiratory volume in 6 s (FEV6) was only measured at qualified sites, and includes 95 completers and 24 drop outs. COPD Chronic obstructive pulmonary disease; FEV1 Forced expiratory volume in 1 s; FVC Forced vital capacity; NSD No significant difference; SGRQ St George’s Respiratory Questionnaire.

in trough FEV1 (Figure 1B [smokers] and Figure 1C [ex-smokers]) when compared with placebo. Smokers had a greater (11.5%) improvement in per cent change in FEV1, from baseline compared with ex-smokers (7.0%). At study end (week 48), the mean difference (± SE) between the tiotropium and placebo treatment groups was 0.14±0.04 L (P<0.001) in the smoker group and 0.08±0.02 L (P<0.0001) in the ex-smoker group, and the difference between the groups was statistically significant (P<0.01).

Tiotropium significantly increased trough FVC and FEV6 throughout the trial when compared with placebo. At week 48, the mean difference (± SE) between the treatment groups was 0.18±0.04 L (P<0.0001) and 0.13±0.05 L (P<0.05) for FVC and FEV6, respectively.

HRQL
Tiotropium significantly improved the SGRQ symptom score (44.4 versus 49.3, P<0.01), impact score (28.5 versus 31.3, P<0.01) and total score (40.9 versus 43.7, P<0.01) when compared with placebo at week 48 (Figure 2A). At week 48, 53% of patients in the tiotropium group had clinically meaningful improvements from baseline (4.0 units or greater improvement) in SGRQ total scores compared with 44% of patients in the placebo group (P=0.052, Cochran-Armitage two-sided trend test). Despite a significant difference at screening between the SGRQ score for smokers and ex-smokers (Table 3), treatment with tiotropium for smokers and ex-smokers resulted in greater improvements in the SGRQ total score when compared with the placebo group, 4.2 units and 2.0 units (Figure 2B).

Rescue medication
Patients receiving tiotropium self-administered approximately six fewer puffs of rescue medication per week compared with...
performed in multiple countries outside of Canada and at
and four fatalities during the post-trial period (two [0.3%] in
two [0.7%] in the placebo group) during the treatment period
There were 15 fatalities (13 [2.1%] in the tiotropium group and
tiotropium group compared with 14.1% in the placebo group.
Overall, 17% of the patients reported a
treatment-emergent serious adverse event, with 18.4% in
3.5% of patients in the tiotropium group and 3.6% of patients
in the placebo group. There were also no difference between the treatment groups in
adverse event over the course of the one-year study was similar
Exacerbations and associated health care utilization
The percentage of patients with at least one COPD exacerbation and the percentage of patients with at least one hospitalization due to a COPD exacerbation did not differ between treatment groups (Table 5). The number of COPD exacerbations per patient-year (adjusted for exposure) on treatment in the tiotropium group was 0.88 compared with 0.92 in the placebo group (P=0.599), and the number of COPD exacerbation days per patient year was 16.13 days in the tiotropium group compared with 16.19 days in the placebo group (P=0.843). Similarly, both the number of hospitalizations and the number of hospitalization days due to a COPD exacerbation did not differ between the two treatment groups (Table 5). There was also no difference between the treatment groups in the number of courses of oral steroids or antibiotics for the treatment of COPD exacerbations (Table 5).

Adverse events
The proportion of patients experiencing a treatment-emergent adverse event over the course of the one-year study was similar in both the tiotropium (78.9%) and placebo (74.1%) groups. The proportion of patients experiencing an adverse event leading to discontinuation was 11.5% and 12.1% in the tiotropium and placebo groups, respectively. Dry mouth occurred in 3.5% of patients in the tiotropium group and 3.6% of patients in the placebo group. Overall, 17% of the patients reported a treatment-emergent serious adverse event, with 18.4% in tiotropium group compared with 14.1% in the placebo group. There were 15 fatalities (13 [2.1%] in the tiotropium group and two [0.7%] in the placebo group) during the treatment period and four fatalities during the post-trial period (two [0.3%] in the tiotropium group and two [0.7%] in the placebo group).

DISCUSSION
Large clinical trials for drug registration of tiotropium were performed in multiple countries outside of Canada and at
clinical research centres. As part of an ongoing postapproval program, the current trial investigated tiotropium in a Canadian health care setting. The trial confirmed that tiotropium is effective at improving lung function in both current smokers and ex-smokers, even with the placebo group already receiving most elements of usual care.

There was some speculation that current smoking may affect the response to tiotropium, as is seen in previous studies with corticosteroid treatment in asthma (7) and bronchodilator treatment in COPD (8), but this was not observed in the current study. This may be due to the substantial differences between the smoker and ex-smoker subgroups, and it would have been better to stratify the patients before randomization to ensure balanced groups. Smoking status was recorded at screening but was not confirmed at study completion by either asking the patient or by measuring serum cotinine levels. This study does show, however, that regardless of ongoing physician attempts to promote smoking cessation, the approximately 100 mL or 10% improvement in lung function with tiotropium in patients already receiving the benefits of usual care will still be realized.

Baseline trough FEV1 and absolute FEV1 were lower in ex-smokers compared with smokers. This may have been due to a form of selection bias in that more severe patients may be more committed to smoking cessation.

The smaller gain in FEV1 with tiotropium in ex-smokers could be attributed to greater disease severity and therefore to less potential for reversibility compared with current smokers. However, his hypothesis has been refuted by Calverley et al (20), who found that baseline lung function (with FEV1 ranging from 0.5 L to 2.0 L) does not influence the absolute improvement in FEV1 following bronchodilatation. Although matching smokers and nonsmokers for disease severity would have been preferable, we believe that the observation that tiotropium is effective in current smokers is valid.

In previous tiotropium studies (9,10), the improvement in FEV1 was 120 mL to 150 mL compared with placebo or ipratropium. The mean improvement in FEV1 of approximately 100 mL observed in the present study may reflect the fact that patients in the placebo group were allowed to take LABAs, which were usually excluded in previous studies. In one recent

**Figure 1** Mean trough forced expiratory volume in 1 s (FEV1) at baseline and at weeks 2, 11, 30 and 48 in all patients (A), smokers (B) and ex-smokers (C). Adjusted means ± SE are shown.
study by Niewoehner et al (13), which did permit the concomitant use of LABAs, the difference in trough FEV$_1$ between tiotropium and placebo was also 100 mL. The difference between the groups might have been larger if there had been fewer drop outs of sicker patients in the placebo group.

FVC and FEV$_6$ (secondary end points) also improved with tiotropium compared with the placebo group. Again, the mean improvement in FVC (180 mL) was slightly less than the 210 mL to 290 mL improvement found in the placebo- or ipratropium-controlled trials (9,10). Swanney et al (21) showed that FEV$_6$ is more reproducible than FVC and may be more relevant in a standard clinic setting. Unfortunately, the 130 mL improvement in FEV$_6$ cannot be compared with other tiotropium studies, because this is the first time that it has been assessed in a clinical trial with tiotropium and the measurement was only performed at qualified sites as a pilot assessment.

The use of rescue medication provides an indication of the degree of breathlessness experienced by the patient. In the current study, rescue medication use was significantly reduced in the tiotropium group compared with the placebo group. By improving lung function, tiotropium relieves breathlessness. In other studies, tiotropium consistently reduced shortness of breath as measured in the transition dyspnea score and decreased use of rescue medication compared with placebo, as demonstrated Brusasco et al (11) and Vincken et al (10).

As with dyspnea, HRQL was better at the end of the one-year trial, with statistically significant improvements in the SGRQ total score as seen by the improvements in the symptoms and impacts domains. The difference between the treatment groups was slightly less than that observed in previous placebo- and ipratropium-controlled studies (3.7 and 3.3 units, respectively) (9,10). The difference in SGRQ scores might have been larger if there had been fewer drop outs of sicker patients in the placebo group. However, greater than one-half of the tiotropium patients had a clinically meaningful improvement in the SGRQ total score. This is an important, validated subjective improvement that is comparable with results from other tiotropium studies (9). The large improvement in the placebo group is certainly more than would be expected. Perhaps this is explained by the halo effect of being in a study with additional monitoring by the clinic staff, enhanced compliance with their concomitant medication (LABA plus inhaled corticosteroids) and, potentially, the poorer responders dropping out. The clinically significant improvement in the SGRQ total score for smokers compared with the ex-smokers is consistent with greater improvement in lung function in smokers.

The observed lack of a significant difference between treatment groups in exacerbation parameters is in direct contrast to the results from the Spiriva (Boehringer Ingelheim Canada) tiotropium clinical trial program to date (9,11,13,14). There are a number of potential explanations for this finding. The
trial was not powered to detect a reduction in exacerbations. In addition, an inclusion criterion was amended to permit patients who were less likely to exacerbate to enter the trial (ie, those patients who had only experienced one COPD exacerbation in the past two years rather than those who had experienced a COPD exacerbation in the past 12 months). Had we realized during enrolment what was recently reported by FitzGerald et al (22) that 46.9% of Canadian patients with moderate to severe COPD might not have an exacerbation during one year, we would not have allowed the change to the inclusion criteria. Finally, commercial tiotropium became available on the market during the study. This may have contributed to the observed higher discontinuation rate in the placebo group (12.5%) compared with the tiotropium group (7.4%) early on in the study (ie, by day 50) and may have resulted in a selection bias. Because patients in the tiotropium group remained in the trial for a longer duration than the patients in the placebo group, they may have experienced more respiratory events. Adjusting for the length of exposure diminished the apparent difference between the two treatment arms and is indicative of nonrandom discontinuation influencing the results.

The low exacerbation and hospitalization rates in the placebo group in the present study may reflect, in part, participation in a self-management plan, an increasingly popular treatment strategy in Canada with proven efficacy in reducing the utilization of health care services (23).

Problems associated with differential discontinuation rates between the active and placebo groups in major COPD trials have been discussed by Decramer et al (24). They concluded that premature discontinuation is not completely random, with sicker patients discontinuing earlier than less sick patients, thereby enriching the remaining study group with healthier patients. In the current study, a higher percentage of patients in the ‘drop out population’ had a history of cardiac and respiratory disorders, in association with a higher use of both cardiac and respiratory medications at baseline. Additionally, the drop out population had more severe COPD at baseline, as assessed by smoking history, lung function, oxygen use and respiratory medications compared with patients who completed the trial, which may reflect a signal toward selection bias. Given the higher drop out rate in the placebo group, the unintentional enrichment of the healthy patients in this group may, in part, explain the lack of a significant difference between the two treatment groups in terms of exacerbations. In addition, Calverley et al (25) found that patients withdrawing from their study’s placebo group had a more rapid decline in FEV1 and more exacerbations than the active group. Perhaps if the current placebo group had been followed after study withdrawal, it may have been determined that they too had exacerbations after they dropped out of the study. However, withdrawn patients were not systematically followed up after they dropped out. Therefore, the poststudy exacerbation status was not available for comparison with the patients who remained in the study. This may have permitted an evaluation of any imbalances following premature discontinuation.

The mortality rate in the current placebo group was much lower (0.7% per year) than in the placebo or ipratropium control arms in the pivotal one-year tiotropium studies (1.9% and 1.7%) (9,10). As with the issue regarding exacerbations, this large difference probably reflects the early drop out of sicker patients and the fact that the remaining patients in the placebo group had better-controlled disease. The 2.1% mortality rate for the tiotropium group was comparable with that observed in other one-year studies of patients with moderate to severe COPD (2.0% to 3.5%) (26), and it was comparable to the rate in other tiotropium studies (1.3% to 2.5%) (9,10,14).

SUMMARY AND CONCLUSION

Compared with the placebo group, tiotropium improved lung function in patients with moderate to severe COPD. There was a treatment response as assessed by FEV1 in both smokers and ex-smokers. The improvements in HRQL and the decreased use of rescue medication support lung function outcomes. The lack of a significant difference in exacerbation rates between the treatment groups cannot be completely explained, especially given positive data in other published tiotropium studies. Tiotropium is considered to be safe and effective in the treatment of patients with moderate to severe COPD even when patients are allowed other concomitant pharmacotherapies.

ACKNOWLEDGEMENTS: This study was funded by Boehringer Ingelheim Canada Ltd and Pfizer Canada.

ETHICS: The study was approved by either local institutional ethics or a centralized ethics board. Participants in the present study gave written, informed consent.

CONFLICTS OF INTEREST: Drs Chan, Maltais and Ford have been members of advisory boards for a number of pharmaceutical companies, including the sponsors of this trial. They are also members of Speakers Bureaux for these companies. Chris Sigouin of the University of Toronto and the founder of Numbers Now Inc performed the statistical analyses for this study. Jennifer Haddon is an employee of Boehringer Ingelheim.

SAFE INVESTIGATORS: John C Acres (Nova Scotia), Didar Ahmad (Ontario), Ronald Akhras (Quebec), Michael Alexander (Ontario), Ross C Anand (British Columbia), John Anthony (Ontario), Allan Bailey (Saskatchewan), Aras Balys (Ontario), Meyer S Balter (Ontario), Spencer Barclay (Nova Scotia), John Bartlett (Ontario), Kenneth Bayly (Saskatchewan), Paul Begun (Quebec), Steven Benze (Ontario), Birubi Biman (Ontario), Harry Birman (Ontario), Graham Bishop (Newfoundland), Stephen P Blackie (British Columbia), Jaques Bouchard (Quebec), Joseph F Braidy (Quebec), Andrew Braude (Ontario), Sarah Lynn Boder (British Columbia), Dieter Bruckschwaiger (Ontario), Maria Bukowskjy (Ontario), Kenneth Butto (Ontario), Amarjit Cheema (Ontario), Joseph (Sin Ming) Chien (Ontario), Thomas P Connolly (British Columbia), Terrance Cooligan (Ontario), Richard Alan Dabrusin (Quebec), Robert Dales (Ontario), Dan Dannati (Saskatchewan), Anna Day (Ontario), Anthony Dowell (Quebec), Gordon Dyck (Manitoba), Frank Ervin (British Columbia), Alan Faier (Ontario), Didier Fay (Quebec), Richard R Feige (British Columbia), Tharwat A Fera (British Columbia), Stephen Field (Alberta), Serge Filion (Quebec), Sandy Finkelstein (Ontario), John Mark Fitzgerald (British Columbia), Gordon T Ford (Alberta), Monique I S Forse (Ontario), George Fox (Newfoundland), Kristen Fraser (Alberta), Jan Fraser (Ontario), Michel A Gagnon (Quebec), Serge Goulet (Quebec), Kempe Gowda (Saskatchewan), Ron Grossman (Ontario), Cindy Hamielec (Ontario), Frederick Hargreave (Ontario), Randolf Hart (Newfoundland), Kay Ho (British Columbia), Richard Hodder (Ontario), Lawrence A Homik (Manitoba), Jeannette Janzen (Quebec), David Kanawaty (Ontario), Richard Hodder (Ontario), Lawrence A Homik (Manitoba), Jeannette Janzen (Quebec), David Kanawaty (Ontario),
REFERENCES


7. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Piyush Patel (Ontario), Leonard Peress (Ontario), Serge Puksa (Ontario), Winston D Rajkumar (Ontario), Warren P Ramesh (Alberta), Julian Raphael (Alberta), Donald Rhodes (Ontario), David Ross (Ontario), Michel Y Rouleau (Quebec), David Ian Small (Quebec), Mohunailah Soowamber (Quebec), Ron Starra (Quebec), David Stubbing (Ontario), Guy Tellier (Québec), Peter Thomas (Ontario), Frances Tung (Ontario), Richard Tytus (Ontario), John J Vlasschaert (Ontario), Ernest L York (Alberta), Noz Zamal (Ontario).

